Xiangmei Chen

Tenured Associate Professor, Research Fellow, Doctoral Supervisor, Independent PI

Contact Information

Email: xm_chen6176@bjmu.edu.cn

Research Focus

Mechanisms of HBV-host interactions; Pathogenesis, diagnosis, and therapeutic strategies for HBV and associated liver diseases.

Personal Profile

Deputy Director of the Department of Microbiology, Peking University Health Science Center.

Currently serves as a member of the Chinese Society of Medical Virology; Standing Committee Member of the Beijing Society of Medical Virology; and Standing Committee Member of the Liver Disease Committee, Beijing Preventive Medicine Association.

Key contributions include: Proposed a novel mechanism of HBV integration in carcinogenesis; identified the host protein TIAR as a key regulator of selective translation of HBV pregenomic RNA; established the correlation between intrahepatic TP53BP2 levels and functional cure in hepatitis B patients following interferon therapy.

As a principal investigator, she has undertaken more than 20 research projects, including the National Major Science and Technology Project for Infectious Diseases, the "14th Five-Year" Key R&D Program, National Natural Science Foundation of China, and Beijing Natural Science Foundation Programs. She has published nearly 60 research papers in domestic and international journals as corresponding author (including co-corresponding). As a completer, she won two Second Prize of the National Science and Technology Progress Award (8th contributor) and Second Prize of the Chinese Medical Science and Technology Award (2nd contributor).

Representative Publications

1. Zhang T^#, Zheng H^#, Lu D^#, Guan G, Li D, Zhang J, Liu S, Zhao J, Guo JT*, Lu F*, Chen X*. RNA binding protein TIAR modulates HBV replication by tipping the balance of pgRNA translation.  Signal Transduct Target Ther . (2023)

2. Guan G^#, Zhang T^#, Ning J^#, Tao C^#, Gao N^#, Zeng Z, Gao H, Chen C, Yang J, Zhang J, Gu W, Yang E, Liu R, Guo X, Ren S, Wang L, Wei G, Zheng S, Gao Z*, Chen X*, Lu F*, Chen X*. Higher TP53BP2 expression is associated with HBsAg loss in peginterferon-alpha-treated chronic hepatitis B.  J Hepatol.  (2024)

3. Ning J^#, Wang J^#, Zheng H, Peng S, Mao T, Wang L, Yu G, Liu J, Liu S, Zhang T, Ding S*, Lu F*, Chen X*. Solely HBsAg intrauterine exposure accelerates HBV clearance by promoting HBs-specific immune response in the mouse pups.  Emerg Microbes Infect.  (2022)

4. Zao X^#, Cheng J^#, Shen C, Guan G, Feng X, Zou J, Zhang J, Liu T, Zheng H, Zhang T, Wang J, Liu J, Li D, Lu F*, You F*, Chen X*. NFATc3 inhibits hepatocarcinogenesis and HBV replication via positively regulating RIG-I-mediated interferon transcription.  Oncoimmunology.  (2021)

5. Liu Y^#, Liu H^#, Hu Z^#, Ding Y^#, Pan XB, Zou J, Xi J, Yu G, Huang H, Luo MT, Guo F, Liu S, Sheng Q, Jia J, Zheng YT, Wang J, Chen X*, Guo JT*, Wei L*, Lu F*. Hepatitis B virus virions produced under nucleos(t)ide analogue treatment are mainly not infectious because of irreversible DNA chain termination.  Hepatology.  (2020)